Skip to main content
Publications
Herring WL, Gallagher ME, Shah N, Morse KC, Mladsi D, Dong OM, Chawla A, Leiding JW, Zhang L, Paramore C, Andemariam B. Cost-effectiveness of lovotibeglogene autotemcel (lovo-cel) gene therapy for patients with sickle cell disease and recurrent vaso-occlusive events in the United States. Pharmacoeconomics. 2024 Apr 29. doi: 10.1007/s40273-024-01385-9
Aiyegbusi OL, Cruz Rivera S, Roydhouse J, Kamudoni P, Alder Y, Anderson N, Baldwin RM, Bhatnagar V, Black J, Bottomley A, Brundage M, Cella D, Collis P, Davies EH, Denniston AK, Efficace F, Gardner A, Gnanasakthy A, Golub RM, Hughes SE, Jeyes F, Kern S, King-Kallimanis BL, Martin A, McMullan C, Mercieca-Bebber R, Monteiro J, Peipert JD, Quijano-Campos JC, Quinten C, Rantell KR, Regnault A, Sasseville M, Schougaard LMV, Sherafat-Kazemzadeh R, Snyder C, Stover AM, Verdi R, Wilson R, Calvert MJ. Recommendations to address respondent burden associated with patient-reported outcome assessment. Nat Med. 2024 Mar;30(3):650-9. doi: 10.1038/s41591-024-02827-9
Stattin P, Westerberg M, Franck Lissbrant I, Hjalm-Eriksson M, Kjellman A, Ullen A, Vassilev Z, Sandstrom P, Weinrib R, Martinez D, Garcia de Albeniz Martinez X. Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden. Clin Genitourin Cancer. 2022 Sep 9;S1558-7673(22):00194-X. doi: 10.1016/j.clgc.2022.09.002
Spelman T, Herring WL, Zhang Y, Tempest M, Pearson I, Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand’Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis VG, Kalincik T, Butzkueven H. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in the United Kingdom. Pharmacoeconomics. 2022 Mar;40(3):323-39. doi: 10.1007/s40273-021-01106-6.
Fan W, Nittala MG, Fleming A, Robertson G, Uji A, Wykoff CC, Brown DM, van Hemert J, Ip M, Wang K, Falavarjani KG, Singer M, Sagong M, Sadda S. Relationship between retinal fractal dimension and nonperfusion in diabetic retinopathy on ultrawide-field fluorescein angiography. Am J Ophthalmol. 2020 Jan 1;209:99-106. doi: 10.1016/j.ajo.2019.08.015
Fan W, Nittala MG, Velaga SB, Hirano T, Wykoff CC, Ip M, Lampen SIR, van Hemert J, Fleming A, Verhoek M, Sadda SR. Distribution of nonperfusion and neovascularization on ultrawide-field fluorescein angiography in proliferative diabetic retinopathy (RECOVERY study): report 1. Am J Ophthalmol. 2019 Oct 1;206:154-60. doi: 10.1016/j.ajo.2019.04.023
Mascarenhas J, Lalitha P, Prajna NV, Srinivasan M, Das M, D'Silva SS, Oldenburg CE, Borkar DS, Esterberg EJ, Lietman TM, Keenan JD. Acanthamoeba, fungal, and bacterial keratitis: a comparison of risk factors and clinical features. Am J Ophthalmol. 2014 Jan;157(1):56-62. doi: 10.1016/j.ajo.2013.08.032